1:15 pm Next Generation Tetravalent Bispecific Antibodies for Cancer Immunotherapy

Time: 1:15 pm
day: Conference Day One


  • Discover F-star’s unique approach to making bispecific tetravalent antibodies in the Fc
  • Description of the process to produce a conditional CD137 agonist Fcab
  • FS222 bispecific uses of the CD137 agonist Fcab, in combination with a PD-L1 targeting Fab
  • Discuss the benefits of FS222 in being tetravalent